Background: It is unknown whether five-year overall survival (OS) differs and to what extent between testicular germ-cell tumor (TGCT) patients and age-matched male population-based controls. Materials: We identified newly diagnosed (2004–2014) TGCT patients within Surveillance Epidemiology and End Results database 2004–2019. We compared OS between non-seminoma (NS-TGCT) and seminoma (S-TGCT) patients relative to age-matched male population-based controls based on Social Security Administration Life-Tables. Smoothed cumulative incidence plots displayed cancer-specific mortality (CSM) vs. other-cause mortality (OCM). Results: Of all 20,935 TGCT patients, 43% had NS-TGCT and 57% had S-TGCT. Of NS-TGCT patients, 63% were stage I vs. 16% stage II vs. 21% stage III. Of S-TGCT patients, 86% were stage I vs. 8% were stage II vs. 6% stage III. Five-year OS differences between NS-TGCT patients vs age-matched male population-based controls were 97 vs. 99% (Δ = 2%) for stage I, 96 vs. 99% (Δ = 3%) for stage II, 76 vs 98% (Δ = 22%) for stage III. Five-year OS differences between S-TGCT patients vs age-matched male population-based controls were 97 vs. 98% (Δ = 1%) for stage I, 95 vs. 97% (Δ = 2%) for stage II, 87 vs. 98% (Δ = 11%) for stage III. OCM rates ranged from 1 to 3% in NS-TGCT patients and from 2 to 4% in S-TGCT patients. Conclusion: The OS difference between NS-TGCT patients vs. age-matched male population-based controls was invariably higher across all stages (2–22%) than for S-TGCT patients (1–11%). Reassuringly, OCM rates were marginal in stage I and stage II patients. Conversely, higher OCM rates were recorded in stage III patients.
Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls / Morra, S.; Piccinelli, M. L.; Cano Garcia, C.; Tappero, S.; Barletta, F.; Incesu, R. -B.; Scheipner, L.; Baudo, A.; Tian, Z.; Saad, F.; Mirone, V.; Califano, G.; Colla' Ruvolo, C.; Shariat, S. F.; de Cobelli, O.; Musi, G.; Chun, F. K. H.; Terrone, C.; Briganti, A.; Tilki, D.; Ahyai, S.; Carmignani, L.; Longo, N.; Karakiewicz, P. I.. - In: INTERNATIONAL UROLOGY AND NEPHROLOGY. - ISSN 0301-1623. - 55:12(2023), pp. 3119-3128. [10.1007/s11255-023-03763-2]
Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls
Morra S.
Primo
;Barletta F.;Mirone V.;Califano G.;Colla' Ruvolo C.;Musi G.;Longo N.Penultimo
;
2023
Abstract
Background: It is unknown whether five-year overall survival (OS) differs and to what extent between testicular germ-cell tumor (TGCT) patients and age-matched male population-based controls. Materials: We identified newly diagnosed (2004–2014) TGCT patients within Surveillance Epidemiology and End Results database 2004–2019. We compared OS between non-seminoma (NS-TGCT) and seminoma (S-TGCT) patients relative to age-matched male population-based controls based on Social Security Administration Life-Tables. Smoothed cumulative incidence plots displayed cancer-specific mortality (CSM) vs. other-cause mortality (OCM). Results: Of all 20,935 TGCT patients, 43% had NS-TGCT and 57% had S-TGCT. Of NS-TGCT patients, 63% were stage I vs. 16% stage II vs. 21% stage III. Of S-TGCT patients, 86% were stage I vs. 8% were stage II vs. 6% stage III. Five-year OS differences between NS-TGCT patients vs age-matched male population-based controls were 97 vs. 99% (Δ = 2%) for stage I, 96 vs. 99% (Δ = 3%) for stage II, 76 vs 98% (Δ = 22%) for stage III. Five-year OS differences between S-TGCT patients vs age-matched male population-based controls were 97 vs. 98% (Δ = 1%) for stage I, 95 vs. 97% (Δ = 2%) for stage II, 87 vs. 98% (Δ = 11%) for stage III. OCM rates ranged from 1 to 3% in NS-TGCT patients and from 2 to 4% in S-TGCT patients. Conclusion: The OS difference between NS-TGCT patients vs. age-matched male population-based controls was invariably higher across all stages (2–22%) than for S-TGCT patients (1–11%). Reassuringly, OCM rates were marginal in stage I and stage II patients. Conversely, higher OCM rates were recorded in stage III patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
